Afatinib is an orally effective epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) used in the treatment of ERBB1-mutant lung cancer, and lapatinib has been widely applied in treating ErbB2-overexpressing breast cancer. Here, ERBB2 is linked to lung carcinoma.